Corneal crosslinking shows favourable long-term outcomes


Studies with follow-up of 2 to 6 years show that corneal crosslinking for progressive keratectasia is safe and induces long-term structural changes.

Data showed that CXL results in a significant keratometric flattening effect that is stable in most eyes, while causing minimal complications or significant best spectacle-corrected visual acuity (BSCVA) loss, noted Prof. Seiler, professor of ophthalmology, University of Zurich, and chairman, IROC Zurich, Switzerland.

Related Videos
Dr Adam Muzychuk discusses his ASCRS presentation
Gret Kunst, CEO of Aurion Biotech
Esen K. Akpek, MD, Professor at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, converses via zoom with David Hutton of Ophthalmology Times
Greg Kunst, CEO of Aurion Biotech
Trukera Medical rebranding ushers in new era of expansion into cornea market
© 2024 MJH Life Sciences

All rights reserved.